성인 급성 골수성 백혈병의 완전관해 유도요법 - TAD 요법과 Augmented TAD 3 ~ 10 요법의 비교 - = Complete Remission Induction for Patients with Acute Myelogenous Leukemia - The regimens of clasical TAD versus augmented TAD 3 ~ 10

다국어 초록 (Multilingual Abstract)

A retrospective study was performed for 3g patients with acute myelogenous leukemia, who were treated with classical TAD regimen(23 patients) or augmented TAD 3~10 regimen(16 patients) as a remission induction chemotherapy. Complete remission(CR, of which definition is excluding relapse within 3 months after application of chemotherapy ) rate, duration of remission, were compared between each group. The CR rate in augmented TAD 3~10 group was 81.3%, and was superior to that in classical TAD group (56.5%). Overall CR rate was 66.7%. The median duration of remission in all was 10.5 months(3~44), in classical TAD group, 13.1 months(5~44), and in augmented TAD 3~10 group, 7.8months (3~19). The duration of remission would be prolonged, if we perform long term follow up study in augmented TAD 3~10 group. In patients with consolidation chemotherapy after CR, the median duration of remission(13.5 months, range 344 months) was longer than that(7.6 months, range 311 months) in patients without consolidation chemotherapy. Our data suggests that: (1) augmented TAD 3~10 regimen, which was modified from conventional TAD regimen by adding cytosine arabinoside of which function is killing the recruit S phase blasts on day 8 and 10, for 3 days, was superior to classical TAD regimen for induction chemotherapy of acute myelogenous leukemia, (2) consolidation chemotherapy after CR would prolong the duration of remission in patients with acute myelogenous leukemia.